Works by Yang, Xue‐Ning


Results: 30
    1

    Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules.

    Published in:
    Journal of Extracellular Vesicles, 2019, v. 8, n. 1, p. 1, doi. 10.1080/20013078.2019.1663666
    By:
    • Zhang, Jia-Tao;
    • Qin, Hao;
    • Man Cheung, Fiona Ka;
    • Su, Jian;
    • Zhang, Da-Dong;
    • Liu, Shi-Yi;
    • Li, Xiao-Fang;
    • Qin, Jing;
    • Lin, Jun-Tao;
    • Jiang, Ben-Yuan;
    • Song Dong;
    • Liao, Ri-Qiang;
    • Qiang, Nie;
    • Yang, Xue-Ning;
    • Tu, Hai-Yan;
    • Zhou, Qing;
    • Yang, Jin-Ji;
    • Zhang, Xu-Chao;
    • Zhang, Ya-Nan;
    • Wu, Yi-Long
    Publication type:
    Article
    2
    3

    Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial.

    Published in:
    Signal Transduction & Targeted Therapy, 2023, v. 8, n. 1, p. 1, doi. 10.1038/s41392-022-01286-3
    By:
    • Zhong, Wen-Zhao;
    • Yan, Hong-Hong;
    • Chen, Ke-Neng;
    • Chen, Chun;
    • Gu, Chun-Dong;
    • Wang, Jun;
    • Yang, Xue-Ning;
    • Mao, Wei-Min;
    • Wang, Qun;
    • Qiao, Gui-Bin;
    • Cheng, Ying;
    • Xu, Lin;
    • Wang, Chang-Li;
    • Chen, Ming-Wei;
    • Kang, Xiao-Zheng;
    • Yan, Wan-Pu;
    • Liao, Ri-Qiang;
    • Yang, Jin-Ji;
    • Zhang, Xu-Chao;
    • Liu, Si-Yang
    Publication type:
    Article
    4
    5
    6

    Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non‐small cell lung cancers.

    Published in:
    Thoracic Cancer, 2022, v. 13, n. 9, p. 1333, doi. 10.1111/1759-7714.14393
    By:
    • Zhang, Jia−Tao;
    • Dong, Song;
    • Ji, Li−Yan;
    • Zhou, Jia−Ying;
    • Chen, Zhi− Hong;
    • Su, Jian;
    • Zhu, Qing−Ge;
    • Wang, Meng−Min;
    • Ke, E−E.;
    • Sun, Hao;
    • Li, Xue−Tao;
    • Yang, Jin−Ji;
    • Zhou, Qing;
    • Zhang, Xu− Chao;
    • Gao, Xuan;
    • Yang, Xue−Ning;
    • Xia, Xuefeng;
    • Yi, Xin;
    • Zhong, Wen−Zhao;
    • Wu, Yi−Long
    Publication type:
    Article
    7

    High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer.

    Published in:
    Thoracic Cancer, 2021, v. 12, n. 19, p. 2564, doi. 10.1111/1759-7714.14137
    By:
    • Feng, Hui‐Bo;
    • Chen, Yu;
    • Xie, Zhi;
    • Jiang, Jie;
    • Zhong, Yu‐Min;
    • Guo, Wei‐Bang;
    • Yan, Wen‐Qing;
    • Lv, Zhi‐Yi;
    • Lu, Dan‐Xia;
    • Liang, Hong‐Ling;
    • Xu, Fang‐Ping;
    • Yang, Jin‐Ji;
    • Yang, Xue‐Ning;
    • Zhou, Qing;
    • Zhang, Dong‐Kun;
    • Zhang, Zhou;
    • Chuai, Shao‐Kun;
    • Zhang, Heng‐Hui;
    • Wu, Yi‐Long;
    • Zhang, Xu‐Chao
    Publication type:
    Article
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22

    Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.

    Published in:
    Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 471, doi. 10.1007/s00262-017-2098-4
    By:
    • Zhang, Xu-chao;
    • Cao, Xu;
    • Sun, Chun;
    • Xie, Zhi;
    • Guo, Jian-jun;
    • Yang, Jin-ji;
    • Yang, Xue-ning;
    • Dai, Hang-jun;
    • Li, Su-chun;
    • Xu, Xin-ran;
    • Zuo, Yun-xia;
    • Chen, Meng;
    • Koeppen, Hartmut;
    • He, Jing;
    • Kiermaier, Astrid;
    • Shames, David;
    • Cheng, Gang;
    • Wu, Yi-long
    Publication type:
    Article
    23
    24
    25
    26
    27
    28

    Lung Cancer Treatment Disparities in China: A Question in Need of an Answer.

    Published in:
    Oncologist, 2014, v. 19, n. 10, p. 1084, doi. 10.1634/theoncologist.2014-0007
    By:
    • Yang, Lu‐Lu;
    • Zhang, Xu‐Chao;
    • Yang, Xue‐Ning;
    • Yang, Jin‐Ji;
    • Wang, Zhen;
    • Chen, Hua‐Jun;
    • Yan, Hong‐Hong;
    • Xu, Chong‐Rui;
    • Guan, Ji‐Lin;
    • He, Yan‐Yan;
    • Zhong, Wen‐Zhao;
    • An, She‐Juan;
    • Wu, Yi‐Long
    Publication type:
    Article
    29

    Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma‐like carcinoma.

    Published in:
    Clinical & Translational Immunology, 2024, v. 13, n. 6, p. 1, doi. 10.1002/cti2.1515
    By:
    • Zhong, Yu‐Min;
    • Chen, Ji;
    • Jiang, Jie;
    • Zhou, Wen‐Bin;
    • Gao, Ling‐Ling;
    • Zhang, Shui‐Lian;
    • Yan, Wen‐Qing;
    • Chen, Yu;
    • Zhang, Dong‐Kun;
    • Lu, Dan‐Xia;
    • Lv, Zhi‐Yi;
    • Xie, Zhi;
    • Huang, Ying;
    • Guo, Wei‐Bang;
    • Wang, Bin‐Chao;
    • Yang, Jin‐Ji;
    • Yang, Xue‐Ning;
    • Wu, Yi‐Long;
    • Zhang, Xu‐Chao
    Publication type:
    Article
    30